Key result
Higher non-HDL-C is linked to ~2% higher odds of severe post-transplant CAV per mg/dL.
Why the study?
Cardiac allograft vasculopathy is a leading cause of morbidity and mortality after heart transplantation, yet contemporary studies examining post-transplant lipid management, cardiometabolic derangements, and their impact on CAV are limited.
Does post-transplant elevation of atherogenic lipids increase the risk of cardiac allograft vasculopathy and major adverse cardiovascular events in heart transplant recipients?
Cohort (n=87)
No
Does post-transplant elevation of atherogenic lipids increase the risk of cardiac allograft vasculopathy and major adverse cardiovascular events in heart transplant recipients?
Answers are grounded in this paper and cite their sources.
Atherogenic lipids (LDL-C, non-HDL-C, triglycerides, and remnant cholesterol) rise significantly within 2 years after heart transplantation despite routine moderate-intensity statin use, and these increases are independently associated with cardiac allograft vasculopathy and MACE.
BACKGROUND: Cardiac allograft vasculopathy (CAV) is a leading cause of morbidity and mortality after heart transplantation (HTx). There are limited contemporary studies examining post-transplant lipid management and cardiometabolic health. OBJECTIVE: We study the burden of cardiometabolic derangements post transplantation and its impact on CAV in a modern cohort of HTx recipients. METHODS: All HTx recipients between January 2019 and December 2020, with 2 lipid assessments and angiographic surveillance were included. Logistic regression was used to assess association of lipid levels with cardiovascular outcomes and CAV. RESULTS: Among 87 HTx recipients, atherogenic lipids were significantly elevated after Htx. Median low-density lipoprotein cholesterol increased from a baseline level of 69.5 mg/dL to 86.5 mg/dL, p = .002, non-high-density lipoprotein cholesterol (non-HDL-C) 91.5 mg/dL to 118 mg/dL, p < .001, triglycerides 94.5 mg/dL to 133 mg/dL, p < .001, and remnant cholesterol 19 mg/dL to 27 mg/dL, p < .001. Increases in non-HDL-C, triglycerides, and remnant cholesterol were significantly associated with increased risk of CAV (Stanford Grade 4 and intimal thickness). Increases in triglycerides and remnant cholesterol were associated with increased risk of composite major adverse cardiovascular events (MACE). CONCLUSION: We demonstrate a significant increase in atherogenic lipids 2 years following transplantation with low use (20%) of high-intensity statin. Increase in atherogenic lipids was associated with increased risk of CAV and increase in triglycerides and remnant cholesterol with increased MACE. Future studies examining cardiometabolic consequences of HTx and optimal treatment strategies to reduce risk of CAV and MACE are needed.
No takes yet. Share an insight, caveat, or question.
Birs et al. (2024) conducted a cohort in Heart transplantation recipients (n=87). Post-transplant atherogenic lipid elevation (non-HDL-C, triglycerides, remnant cholesterol) vs. Baseline pre-transplant lipid levels / lower post-transplant lipid levels was evaluated on Cardiac allograft vasculopathy (Stanford Grade 4 on IVUS at year 2) per mg/dL increase in non-HDL-C (OR 1.022, p=<0.01). Increases in non-HDL-C, triglycerides, and remnant cholesterol were associated with Stanford Grade 4 CAV after heart transplant.
Synapse has enriched 10 related papers. Consider them for comparative context: